Top Markets
#1 QuantixAI QuantixAI +102.23%
#2 龙虾 (Lobster) 龙虾 (Lobster) +29.81%
#3 MetaDAO MetaDAO +26.72%
#4 Pons Pons +25.79%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +25.77%
#6 Rain Rain +25.75%
#7 Bedrock Bedrock +20.69%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +19.32%
#9 Prom Prom +18.01%
#10 Ontology Gas Ontology Gas +17.84%
Coin of the day
QuantixAI QuantixAI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
Classifica tra le azioni #2542
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Prezzo delle azioni
$11.91
Capitalizzazione di mercato
$8.11B
Variazione (1 giorno)
1.67%
Variazione (1 anno)
-16.23%
Paese
ES
Scambia Grifols, S.A. (GRF)

Categoria

Healthcare
EPS per Grifols, S.A. (GRF)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Grifols, S.A., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Grifols, S.A. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $29.85 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $8.65 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $3.55 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $20.39 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $1.26 -
US